Natco undercuts GLP-1 market with ultra-cheap semaglutide vials 

Key Highlights:  

• Natco Pharma has launched its generic semaglutide injection in India on Day 1 of patent expiry under the brands Semanat and Semafull. Approved by CDSCO based on a clinical comparison study, the therapy is indicated for adults with inadequately controlled type 2 diabetes as an adjunct to diet and exercise 

• Natco is introducing semaglutide in multi-dose vial formats (2 mg/1.5 mL, 4 mg/3 mL, 8 mg/3 mL), priced at ~₹1,290/month for lower strengths and ~₹1,750/month for the highest strength, making it the most affordable GLP-1 option in India. The company claims the vial format is ~70% cheaper than pen devices and ~90% lower than innovator pricing, significantly improving access and long-term adherence 

• Expanding its offering, Natco will also launch pen devices in April 2026 (₹4,000–₹4,500/month), while currently being the first to introduce multi-dose vial semaglutide with customised syringes. The company is additionally opening the product for co-marketing partnerships, aiming to widen reach and accelerate adoption across the Indian market. 

Implications: 

By launching Day‑1 multi‑dose vials at ₹1,290–₹1,750 per month and claiming 70–90% discounts vs pens and innovator brands, Natco is setting the floor on GLP‑1 pricing and intensifying the emerging “price war” in India’s semaglutide market. 
The first‑to‑market vial format with customised syringes, followed by April 2026 pen devices and openness to co‑marketing deals, positions Natco as a volume‑driven supplier whose ultra‑low pricing and partnership model can rapidly expand GLP‑1 reach into cost‑sensitive segments nationwide.  

Source: Natco | Image: Natco